GlassScriptPhysician profile
Gustavo Rivero
NPI 1790736155
$28,642.94
in general payments reported to CMS, 2019-2025
27 companies · $4,866 in 2025
The $4,866 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $1,065 · 2021: $1,297 · 2022: $1,761 · 2023: $242 · 2024: $507 · 2025: $4,866.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,000 · Food and Beverage: $1,282 · Travel and Lodging: $287 · Education: $45.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,000.00 |
| Food and Beverage | $1,282.40 |
| Travel and Lodging | $286.97 |
| Education | $45.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Skeletal Dynamics INC | $14,732.25 | 2019 | |
| Syndax Pharmaceuticals, INC. | $4,390.89 | 2025 | Revuforj |
| Agios Pharmaceuticals, INC. | $4,034.07 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $1,625.00 | 2022 | |
| Celgene Corporation | $1,541.11 | 2021-2025 | Reblozyl |
| Incyte Corporation | $940.00 | 2020 | |
| Adaptive Biotechnologies Corporation | $301.46 | 2019-2022 | |
| Daiichi Sankyo INC. | $158.09 | 2024-2025 | Vanflyta |
| Pharmaessentia USA Corporation | $124.99 | 2023 | Besremi |
| Abbvie INC. | $98.75 | 2024-2025 | |
| Beone Medicines USA, INC. | $94.57 | 2025 | Brukinsa |
| Novartis Pharmaceuticals Corporation | $91.95 | 2022-2025 | |
| Genzyme Corporation | $82.49 | 2024 | |
| Rigel Pharmaceuticals, INC. | $75.05 | 2023-2024 | Rezlidhia, Tavalisse |
| Legend Biotech USA INC. | $63.97 | 2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $45.27 | 2024 | Empaveli |
| Amgen INC. | $41.25 | 2022 | |
| Pierre Fabre Pharmaceuticals, INC. | $39.14 | 2025 | Hemangeol |
| Teleflex LLC | $29.62 | 2024 | Arrow |
| Pharmacosmos Therapeutics INC. | $23.39 | 2025 | Monoferric |
| Alexion Pharmaceuticals, INC. | $23.10 | 2022 | |
| Astellas Pharma US INC | $23.00 | 2024 | Xospata |
| Glaxosmithkline, LLC. | $21.01 | 2024 | Ojjaara |
| Eisai INC. | $16.39 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.16 | 2019 | |
| Acrotech Biopharma INC. | $11.97 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gustavo Rivero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.